Damoctocog alfa pegol
| Clinical data | |
|---|---|
| Trade names | Jivi |
| Other names | BAY94-9027, antihemophilic factor (recombinant), pegylated-aucl |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C7445H11318N1984O2184S69 |
| Molar mass | 165774.28 g·mol−1 |
Damoctocog alfa pegol, sold under the brand name Jivi is a recombinant DNA-derived, Factor VIII concentrate used to treat hemophilia A.
The most common side effects include headache, cough, nausea, and fever.
Damoctocog alfa pegol was approved for medical use in the United States in August 2018, and in the European Union in November 2018.